alexa A Pilot Study of Nemonoxacin in Patients with Diabetic Foot Infections | OMICS International| Abstract
ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Infect Dis Ther 2019, Vol 7(2): 397
  • DOI: 10.4172/2332-0877.1000397

A Pilot Study of Nemonoxacin in Patients with Diabetic Foot Infections

Benjamin A Lipsky1, Mashra Ganib2, Lee C Rogers3, Jawl-Shan Hwang4, Cheng-Yuan Tsaie, Li-Wen Chang5, Yu-Ting Chang5 and Ming-Chu Hsue5*
1Green Templeton College, University of Oxford, Oxford, UK
2Mercantile Hospital Center, Mercantile Hospital Center, Korsten, South Africa
3Broadlawns Medical Center, Des Moines, iowa, USA
4Chang-Gung Memorial Hospital, Taoyuan, Taiwan
5TaiGen Biotechnology Co. Ltd., Taipei, Taiwan
*Corresponding Author : Ming-Chu Hsue, TaiGen Biotechnology Co. Ltd., Taipei, Taiwan, Tel: +886-2-8177-7072, Email: [email protected]

Received Date: Nov 13, 2018 / Accepted Date: Mar 04, 2019 / Published Date: Mar 11, 2019


Background: Diabetic foot infections (DFIs) are usually caused by a mixture of bacterial pathogens, especially staphylococci (including methicillin-resistant strains). Nemonoxacin, a broad-spectrum non-fluorinated quinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA), could potentially be an effective agent to treat DFIs. The efficacy, safety, pharmacokinetics, and pharmacodynamics of nemonoxacin were evaluated in patients with DFI. Methods: Patients with mild or moderate DFI were treated with nemonoxacin 750 mg orally once daily for 7-14 days in this open-label, single-arm, multi-center study. Clinical and microbiological responses were evaluated. Blood and tissue samples were collected for assessment of the ability of nemonoxacin to penetrate into infected soft tissue wounds. Results: Thirty-eight patients were enrolled, 25 successfully completed the study. The predominant wound isolate was Staphylococcus aureus (in 69.7%), four of which were MRSA. Clinical success rate in evaluable patients at the test-of-cure (TOC) visit was achieved in 95.7% of patients in the intent-to-treat (ITT) and 94.7% in the per-protocol (PP) populations. Microbiological success rate at TOC in ITT and PP populations were 82.6% and 89.5%, respectively. Wound healing response (a validated wound score) demonstrated that the severity of infection was substantially reduced after treatment. Treatment with nemonoxacin was well tolerated. Nemonoxacin was rapidly absorbed and distributed to soft tissue following oral administration, with Cmax,ss attained at ~2 hours after dosing. Drug concentrations in soft tissue were >2.5 times of that in plasma at most sampling points. The ratio of AUC0-24 (tissue/plasma) was 3.08, with fAUC/MICs in plasma ranging from 13.1 to 1747.9, while AUC/MICs in soft tissue were 48.0 to 3200.0. Conclusion: In this small sample of DFI patients, nemonoxacin demonstrated good clinical and microbiological success rates, was well tolerated, and penetrated extensively into infected tissues. These results suggest that oncedaily oral nemonoxacin may be suitable for treating patients with DFI. identifier: NCT00685698.

Keywords: Nemonoxacin; Diabetic foot infections; DFI; Fluoroquinolone; Efficacy; Safety

Citation: Lipsky BA, Ganib M, Rogers LC, Hwang JS, Tsaie CY, et al. (2019) A Pilot Study of Nemonoxacin in Patients with Diabetic Foot Infections. J Infect Dis Ther 7: 397. Doi: 10.4172/2332-0877.1000397

Copyright: © 2019 Lipsky BA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Recommended Conferences
Article Usage
  • Total views: 1025
  • [From(publication date): 0-0 - Jul 12, 2020]
  • Breakdown by view type
  • HTML page views: 953
  • PDF downloads: 72